Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Feng, Jifeng
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5208
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Stu
    Wu JianQiu
    Song YongPing
    Su LiPing
    Zhang MingZhi
    Li Wei
    Hu Yu
    Zhang XiaoHong
    Gao YuHuan
    Niu ZuoXing
    Feng Ru
    Wang Wei
    Peng JieWen
    Li XiaoLin
    Ouyang XueNong
    Wu ChangPing
    Zhang WeiJing
    Zeng Yun
    Xiao Zhen
    Liang YingMin
    Zhuang YongZhi
    Wang JiShi
    Sun ZiMin
    Bai Hai
    Cui TongJian
    Feng JiFeng
    Department of Oncology Jiangsu Cancer Hospital Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Nanjing Jiangsu China
    Department of Hematology Henan Cancer Hospital Zhengzhou Henan China
    Department of Hematology Shanxi Cancer Hospital Taiyuan Shanxi China
    Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China
    Department of Oncology Jilin University First Affiliated Hospital Changchun Jilin China
    Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
    Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China
    Department of Hematology Fourth Hospital of Hebei Medical University Shijiazhuang Hebei China
    Department of Oncology Affiliated Hospital of Shandong Academy of Medical Sciences Jinan Shandong China
    Department of Hematology Medical University Nanfang Hospital Guangzhou Guangdong China
    Department of Oncology Guangdong Foshan First Hospital Foshan Guangdong China
    Department of Oncology Guangdong Zhongshan Peoples Hospital Zhongshan Guangdong China
    Department of Hematology Xiangya Hospital Central South University Changsha Hunan China
    Department of Oncology Fuzhou General Hospital of Nanjing Military Command Fuzhou Fujian China
    Department of Oncology Changzhou First Peoples Hospital Changzhou Jiangsu China
    Department of Oncology Hospital of Chinese Peoples Liberation Army Beijing Chinanow works at Department of Oncology Beijing Shijitan Hospital Capital Medical University Beijing China
    Department of Hematology First Affiliated Hospital of Kunming Medical University Kunming Yunnan China
    Department of Hematology Affiliated Hospital of Neimenggu Medical College Hohhot Huhehaote Inner Mongolia China
    Department of Hematology The Fourth Military Medical University Affiliated Tangdu Hospital Xian Shaanxi China
    Department of Oncology Daqing General Hospital Group Oilfield General Hospital Daqing Heilongjiang China
    Department of Hematology Affiliated Hospital of Guiyang Medical College Guiyang Guizhou China
    Department of Hematology Anhui Provincial Hospital Hefei Anhui China
    Department of Hematology Lanzhou Military Hospital Lanzhou Gansu China
    Department of Oncology Fujian Provincial Hospital Fuzhou Fujian China WeiJing Zhang now works at Department of Oncology Beijing Shijitan Hospital Capital Medical University Beijing China
    中华医学杂志英文版, 2018, 131 (15) : 1767 - 1775
  • [2] Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
    Wu, Jian-Qiu
    Song, Yong-Ping
    Su, Li-Ping
    Zhang, Ming-Zhi
    Lis, Wei
    Hu, Yu
    Zhang, Xiao-Hong
    Gao, Yu-Huan
    Niu, Zuo-Xing
    Feng, Ru
    Wang, Wei
    Peng, Jie-Wen
    Li, Xiao-Lin
    Ouyang, Xue-Nong
    Wu, Chang-Ping
    Zhang, Wei-Jing
    Zeng, Yun
    Xiao, Zhen
    Liang, Ying-Min
    Zhuang, Yong-Zhi
    Wang, Ji-Shi
    Sun, Zi-Min
    Bai, Hai
    Cui, Tong-Jian
    Feng, Ji-Feng
    CHINESE MEDICAL JOURNAL, 2018, 131 (15) : 1767 - 1775
  • [3] A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
    Feng, Jifeng
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Feng, Ru
    Wang, Wei
    Niu, Zuoxing
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changing
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    BLOOD, 2014, 124 (21)
  • [4] The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings
    Celso Arrais Rodrigues
    Poliana Alves Patah
    Yana A. S. Novis
    Chitra Hosing
    Marcos de Lima
    Current Hematologic Malignancy Reports, 2011, 6 : 47 - 57
  • [5] The Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings
    Rodrigues, Celso Arrais
    Patah, Poliana Alves
    Novis, Yana A. S.
    Hosing, Chitra
    de Lima, Marcos
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 47 - 57
  • [6] Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed With Diffuse Large B-Cell Lymphoma
    Griffiths, Robert I.
    Gleeson, Michelle L.
    Mikhael, Joseph
    Dreyling, Martin H.
    Danese, Mark D.
    CANCER, 2012, 118 (24) : 6079 - 6088
  • [7] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [8] Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
    Jianqiu Wu
    Yongping Song
    Liping Su
    Li Xu
    Tingchao Chen
    Zhiyun Zhao
    Mingzhi Zhang
    Wei Li
    Yu Hu
    Xiaohong Zhang
    Yuhuan Gao
    Zuoxing Niu
    Ru Feng
    Wei Wang
    Jiewen Peng
    Xiaolin Li
    Xuenong Ouyang
    Changping Wu
    Weijing Zhang
    Yun Zeng
    Zhen Xiao
    Yingmin Liang
    Yongzhi Zhuang
    Jishi Wang
    Zimin Sun
    Hai Bai
    Tongjian Cui
    Jifeng Feng
    BMC Cancer, 16
  • [9] Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Xu, Li
    Chen, Tingchao
    Zhao, Zhiyun
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Niu, Zuoxing
    Feng, Ru
    Wang, Wei
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changping
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    Feng, Jifeng
    BMC CANCER, 2016, 16
  • [10] Diffuse large-cell B-cell lymphoma: first-line treatment without chemotherapy in frail elderly patients lenalidomide-rituximab combination
    Houtteghem, Tristan Robert-Van
    HEMATOLOGIE, 2023, 29 (06): : 330 - 332
12345